论文部分内容阅读
目的:研究米力农在急性心肌梗死(AMI)泵衰竭患者支架植入术后早期的应用效果.方法:连续选择86例AMI泵衰竭患者行急诊PCI术后,随机分为对照组和观察组各43例,对照组采用毛花苷丙静脉注射(毛花苷丙0.2mg/d,共7d),观察组采用米力农负荷剂量法(负荷量50μg/kg,0.5μg/kg/min持续泵入7d),对比临床效果。结果:2组冠状动脉狭窄程度、病变部位、靶血管数目、支架数目、长度和内径比较差异均无统计学意义。观察组临床有效率明显高于对照组(P<0.05),2组均未出现明显不良反应。随访1个月,2组血清NTproBNP水平较应用前降低,左室射血分数(LVEF)水平升高,观察组较对照组改善更明显(P<0.05);2组干预前后左室舒张末内径(LVEDd)值比较差异均无统计学意义。观察组主要心脏不良事件(MACE)发生率明显低于对照组(P<0.05)。结论:米力农负荷剂量法在AMI泵衰竭患者支架植入术后早期应用有较好的安全性和有效性。
Objective: To study the early application effect of Milrinone in patients with acute myocardial infarction (AMI) pump failure after stent implantation.Methods: 86 consecutive patients with AMI failure were randomly divided into control group and observation group The control group received intravenous injection of Maohua glycosides (0.3 mg / d for 7 days). The rats in the observation group were treated with Milrinone load (loading 50μg / kg, 0.5μg / kg / min) Pump into 7d), compare clinical effect. Results: There was no significant difference between the two groups in the degree of coronary artery stenosis, lesion location, number of target vessels, number of scaffolds, length and diameter. The clinical effective rate in the observation group was significantly higher than that in the control group (P <0.05). No obvious adverse reactions occurred in the two groups. After one month of follow-up, the level of NTproBNP in the two groups was lower than before and the level of left ventricular ejection fraction (LVEF) was higher in the observation group than in the control group (P <0.05). Before and after treatment, the left ventricular end-diastolic diameter (LVEDd) values were no significant difference. The incidence of major cardiac adverse events (MACE) in the observation group was significantly lower than that in the control group (P <0.05). Conclusion: Milrinone loading dose has good safety and efficacy in the early stage after stent implantation in AMI patients with pump failure.